These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 31388135)

  • 1. Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.
    Baillie GS; Tejeda GS; Kelly MP
    Nat Rev Drug Discov; 2019 Oct; 18(10):770-796. PubMed ID: 31388135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.
    Ahmad F; Murata T; Shimizu K; Degerman E; Maurice D; Manganiello V
    Oral Dis; 2015 Jan; 21(1):e25-50. PubMed ID: 25056711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Cyclic Nucleotide Phosphodiesterase-Targeted PET Imaging and Drug Discovery.
    Sun J; Xiao Z; Haider A; Gebhard C; Xu H; Luo HB; Zhang HT; Josephson L; Wang L; Liang SH
    J Med Chem; 2021 Jun; 64(11):7083-7109. PubMed ID: 34042442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDE inhibitors: a new approach to treat metabolic syndrome?
    Lugnier C
    Curr Opin Pharmacol; 2011 Dec; 11(6):698-706. PubMed ID: 22018840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
    Kokkonen K; Kass DA
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():455-479. PubMed ID: 27732797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cyclic nucleotide phosphodiesterases: therapeutic targets in cardiac hypertrophy and failure].
    Barthou A; Kamel R; Leroy J; Vandecasteele G; Fischmeister R
    Med Sci (Paris); 2024; 40(6-7):534-543. PubMed ID: 38986098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase inhibitors.
    Boswell-Smith V; Spina D; Page CP
    Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S252-7. PubMed ID: 16402111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic nucleotide phosphodiesterases (PDEs) and endothelial function in ischaemic stroke. A review.
    Yasmeen S; Akram BH; Hainsworth AH; Kruuse C
    Cell Signal; 2019 Sep; 61():108-119. PubMed ID: 31132399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorder.
    Wen RT; Zhang FF; Zhang HT
    Psychopharmacology (Berl); 2018 Jun; 235(6):1793-1805. PubMed ID: 29663017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic nucleotide phosphodiesterases: critical modulators of endocrine, metabolic, and cardiovascular function and appealing therapeutic targets.
    Manganiello V
    Curr Opin Pharmacol; 2011 Dec; 11(6):646-8. PubMed ID: 22079477
    [No Abstract]   [Full Text] [Related]  

  • 11. The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.
    Nadur NF; de Azevedo LL; Caruso L; Graebin CS; Lacerda RB; Kümmerle AE
    Eur J Med Chem; 2021 Feb; 212():113123. PubMed ID: 33412421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basic and clinical characteristics of PDE 3 inhibitors as cardiotonic agents.
    Endoh M
    Cardiovasc Drugs Ther; 2007 Jun; 21(3):135-9. PubMed ID: 17508272
    [No Abstract]   [Full Text] [Related]  

  • 13. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
    Guo L; Luo L; Ju R; Chen C; Zhu L; Li J; Yu X; Ye C; Zhang D
    Eur J Pharmacol; 2015 Jan; 746():14-21. PubMed ID: 25446933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies.
    Lerner A; Kim DH; Lee R
    Leuk Lymphoma; 2000 Mar; 37(1-2):39-51. PubMed ID: 10721768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.
    Levy I; Horvath A; Azevedo M; de Alexandre RB; Stratakis CA
    Curr Opin Pharmacol; 2011 Dec; 11(6):689-97. PubMed ID: 22047791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases.
    Martinez A; Gil C
    Expert Opin Ther Pat; 2014 Dec; 24(12):1311-21. PubMed ID: 25284693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
    Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
    Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Phosphodiesterase-Protein-Kinase Complexes as Novel Targets for Discovery of Inhibitors with Enhanced Specificity.
    Tulsian NK; Sin VJ; Koh HL; Anand GS
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34063491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABCD of the phosphodiesterase family: interaction and differential activity in COPD.
    Halpin DM
    Int J Chron Obstruct Pulmon Dis; 2008; 3(4):543-61. PubMed ID: 19281073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors.
    Souness JE; Aldous D; Sargent C
    Immunopharmacology; 2000 May; 47(2-3):127-62. PubMed ID: 10878287
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 33.